Pharma News, 2026

A new machine-learning system trained on sparse data predicts molecular formation, cutting months of drug synthesis lab work to days at a fraction of cost.

A new study explores the combined effects of gestational diabetes and prenatal depression, revealing a 43% higher risk of childhood obesity in offspring.

Affinia Therapeutics receives FDA Fast Track designation for AFTX-201, an engineered gene therapy for BAG3-associated dilated cardiomyopathy (DCM) treatment.

Johnson & Johnson secures FDA approval for the Tecvayli and Darzalex Faspro combination to treat adults with relapsed or refractory multiple myeloma.

Phase 2a trial data reveals that adding low-dose alnodesertib to chemotherapy may slow disease progression in platinum-resistant ovarian cancer patients.

Vericel Corporation receives FDA approval for its new state-of-the-art cell therapy manufacturing facility in Burlington, MA to expand MACI production.

HotSpot Therapeutics presents preclinical data for its small molecule IRF5 inhibitor program for systemic lupus at the 15th European Lupus Meeting.

Propanc Biopharma's lead asset PRP shows over 85% tumor growth inhibition in preclinical pancreatic models, offering a promising new metastasis treatment.

Novo Nordisk invests €432m to upgrade its Ireland facility, boosting oral Wegovy (semaglutide) production to meet surging global weight loss drug demand.

NATCO Pharma, partnering with Breckenridge Pharmaceutical, launches generic Pomalidomide capsules in the US, offering affordable blood cancer treatment.

Roche reports its Phase III FENhance 1 trial for fenebrutinib in relapsing multiple sclerosis met its primary endpoint, reducing relapse rates by 51%.

New preclinical study shows engineered CAR macrophages (CARMA) can cross the blood-brain barrier and effectively attack lung cancer brain metastases.